Page 157 - 南京医科大学自然版
P. 157
第46卷第5期 卢森威,彭红红,施 超. 呼吸道合胞病毒(A/B亚型)人群抗体特征及影响因素研究进展[J].
2026年5月 南京医科大学学报(自然科学版),2026,46(5):771-779,784 ·779 ·
review and meta ⁃ analysis[J]. J Infect Dis,2020,222 syncytial virus following the COVID⁃19 pandemic in the
(Suppl 7):S577-S583 US[J]. JAMA Netw Open,2021,4(12):e2141779
[30]KORSTEN K,ADRIAENSSENS N,COENEN S,et al. Bur⁃ [41]RIUS⁃PERIS J M,DEL CARMEN VICENT CASTELLÓ
den of respiratory syncytial virus infection in community⁃ M,LEÓN M P,et al. Changes in entire acute bronchio⁃
dwelling older adults in Europe(RESCEU):an interna⁃ litis seasons before,during,and after the COVID⁃19 pan⁃
tional prospective cohort study[J]. Eur Respir J,2021,57 demic in Spain[J]. Infect Prev Pract,2024,6(4):
(4):2002688 100399
[31]张泰然,王 汀. 呼吸道合胞病毒及其疫苗研究进展[J]. [42]REICHERZ F,XU R Y,ABU⁃RAYA B,et al. Waning im⁃
中国药剂学杂志(网络版),2025,23(1):36-43 munity against respiratory syncytial virus during the coro⁃
ZHANG T R,WANG T. Research progress on respiratory navirus disease 2019 pandemic[J]. J Infect Dis,2022,
syncytial virus and its vaccine[J]. Chinese Journal of 226(12):2064-2068
Pharmaceutical Technology(Online Edition),2025,23 [43]LI Z J,ZHANG H Y,REN L L,et al. Etiological and epi⁃
(1):36-43 demiological features of acute respiratory infections in
[32]LIANG Y,SHAO S,LI X Y,et al. Mutating a flexible re⁃ China[J]. Nat Commun,2021,12(1):5026
gion of the RSV F protein can stabilize the prefusion con⁃ [44]BEWLEY K R,COOMBES N S,GAGNON L,et al. Quan⁃
formation[J]. Science,2024,385(6716):1484-1491 tification of SARS⁃CoV⁃2 neutralizing antibody by wild⁃
[33]姜人月,庄忻雨,田明尧,等. 呼吸道合胞病毒mRNA候 type plaque reduction neutralization,microneutralization
选疫苗的表达、鉴定及免疫效果验证[J]. 中国病原生 and pseudotyped virus neutralization assays[J]. Nat Pro⁃
物学杂志,2024,19(5):497-501 toc,2021,16(6):3114-3140
JIANG R Y,ZHUANG X Y,TIAN M Y,et al. Expression, [45]GUO J Z,LU J S,DU P,et al. Fluorescence reduction neu⁃
identification and immune efficacy verification of a candi⁃ tralization test:a novel,rapid,and efficient method for
date vaccine for respiratory syncytial virus mRNA[J]. characterizing the neutralizing activity of antibodies
Chinese Journal of Pathogenic Biology,2024,19(5): against dengue virus[J]. Curr Issues Mol Biol,2025,47
497-501 (3):140
[34]CABÁN M,RODARTE J V,BIBBY M,et al. Cross⁃protec⁃ [46]程宁宁,苏彦斌,刘美琴,等. 呼吸道合胞病毒血清中和
tive antibodies against common endemic respiratory virus⁃ 抗体检测方法的建立[J]. 微生物学免疫学进展,2024,
es[J]. Nat Commun,2023,14(1):798 52(2):21-27
[35]MAZUR N I,HORSLEY N M,ENGLUND J A,et al. CHENG N N,SU Y B,LIU M Q,et al. Establishment of a
Breast milk prefusion F immunoglobulin G as a correlate method for detecting serum neutralizing antibodies
of protection against respiratory syncytial virus acute against respiratory syncytial virus[J]. Advances in Micro⁃
respiratory illness[J]. J Infect Dis,2019,219(1):59-67 biology and Immunology,2024,52(2):21-27
[36]WANG Q L,LIU N L,WANG Y,et al. Antibody respons⁃ [47]WANG H J,CHEN J X,XUE L H,et al. Establishment of
es to respiratory syncytial virus:a population⁃based cross⁃ a pseudovirus neutralization assay for TGEV[J]. Front
sectional serological study in Southern China,2021[J]. Immunol,2025,16:1558604
Clin Microbiol Infect,2024,30(9):1183-1189 [48]COX F,SAELAND E,THOMA A,et al. RSV A2⁃based
[37]NHAM E,JANG A Y,HYUN H,et al. Age⁃stratified sero⁃ prefusion F vaccine candidates induce RSV A and RSV B
prevalence of respiratory syncytial virus:analysis using cross binding and neutralizing antibodies and provide pro⁃
prefusion F and G protein antibodies[J]. Vaccines(Ba⁃ tection against RSV A and RSV B challenge in preclini⁃
sel),2024,12(5):513 cal models[J]. Vaccines(Basel),2023,11(3):672
[38]LU Y F,CHEN Q H,REN S L,et al. Impact of COVID⁃19 [49] PILIPER E A,REED J C,GRENINGER A L. Clinical
nonpharmaceutical interventions on respiratory syncytial validation of an RSV neutralization assay and analysis of
virus infections in hospitalized children[J]. Influenza cross⁃sectional sera associated with 2021⁃2023 RSV out⁃
Other Respir Viruses,2024,18(4):e13291 breaks to investigate the immunity debt hypothesis[J].
[39]UJIIE M,TSUZUKI S,NAKAMOTO T,et al. Resurgence Microbiol Spectr,2024,12(12):e0211524
of respiratory syncytial virus infections during COVID⁃19 [50]LORENZO M E,HODGSON A,ROBINSON D P,et al.
pandemic,Tokyo,Japan[J]. Emerg Infect Dis,2021,27 Antibody responses and cross protection against lethal
(11):2969-2970 influenza A viruses differ between the sexes in C57BL/6
[40]ZHENG Z,PITZER V E,SHAPIRO E D,et al. Estimation mice[J]. Vaccine,2011,29(49):9246-9255
of the timing and intensity of reemergence of respiratory (下转第784页)

